Trial Profile
Study of Recombinant Zoster Vaccine (RZV-Shingrix) in Patients With Inflammatory Bowel Disease
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2019
Price :
$35
*
At a glance
- Drugs GSK 137173A (Primary)
- Indications Herpes zoster
- Focus Therapeutic Use
- 09 Nov 2018 New trial record
- 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018